

Special Issue

Role of NF- κ B in Cancer

Message from the Guest Editor

This Special Issue focuses on the functional roles of NF- κ B in cancer. NF- κ B has been implicated in numerous physiological and pathological situations, such as diabetes, multiple sclerosis, Alzheimer's disease, inflammatory disease, or cancer. A variety of evidence has also implicated NF- κ B dysregulation in tumor invasion, cell survival, proliferation, angiogenesis, and metastasis. Based on recent papers, we would like to focus on the relationship between NF- κ B and tumorigenic responses that play an important role in cancer initiation, progression and metastasis such as activation of signal pathway, immune surveillance, tumor microenvironment, gene regulation of cytokine and chemokine, inflammation and so on. In addition, we would also like to refine our understanding of how the NF- κ B signaling pathway regulates tumorigenic responses in each type of cancer. In this Special Issue, review articles on basic science and preclinical and clinical findings are warmly welcome to contribute to our understanding of the role of NF- κ B in cancer.

Guest Editor

Dr. Yo Han Hong

Institute for Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Deadline for manuscript submissions

closed (30 September 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/120687

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).